Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4.

2.50
Hdl Handle:
http://hdl.handle.net/10541/88040
Title:
Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4.
Authors:
Zhao, Sha; Moore, James V; Waller, Michael L; McGown, Alan T; Hadfield, John A; Pettit, G R; Pettit, G R; Hastings, David L
Abstract:
There are major potential advantages in non-invasive measurement of preclinical tumour biology and therapeutic response in clinically relevant, internal body sites, notably the ability to follow outcome in individual animals rather than averaging results from groups. We have exploited positron emission tomography (PET) to determine the feasibility of detecting liver metastases in B6D2F1 mice using fluorine-18 fluorodeoxyglucose ([18F]FDG) both before and after treatment by the novel cytotoxic agent, combretastatin A-4. The normal distribution of [18F]FDG in the absence of disease was characterised, with the clear delineation of the brain, the heart and the urinary bladder in all studies. In untreated mice with liver metastases, a strong correlation (r2 = 0.98) was found between the quantitative estimates of [18F]FDG uptake obtained by analysis of PET images, and those obtained from ex vivo assay of liver plus metastases excised immediately after imaging. In this first series, the effective limit of resolution was in livers containing a number of small metastases (range 8-14) with a single volume equivalent of approximately 200 mm3. PET image analysis was concordant with histological measurements in showing that single intraperitoneal doses of combretastatin A-4 resulted in an average 30% volume destruction of metastatic mass by 24 h following administration.
Affiliation:
North West Medical Physics, Christie Hospital (NHS) Trust, Manchester, UK.
Citation:
Positron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. 1999, 26 (3):231-8 Eur J Nucl Med
Journal:
European Journal of Nuclear Medicine
Issue Date:
Mar-1999
URI:
http://hdl.handle.net/10541/88040
DOI:
10.1007/s002590050382
PubMed ID:
10079313
Type:
Article
Language:
en
ISSN:
0340-6997
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorZhao, Shaen
dc.contributor.authorMoore, James Ven
dc.contributor.authorWaller, Michael Len
dc.contributor.authorMcGown, Alan Ten
dc.contributor.authorHadfield, John Aen
dc.contributor.authorPettit, G Ren
dc.contributor.authorPettit, G Ren
dc.contributor.authorHastings, David Len
dc.date.accessioned2009-12-15T16:36:21Z-
dc.date.available2009-12-15T16:36:21Z-
dc.date.issued1999-03-
dc.identifier.citationPositron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4. 1999, 26 (3):231-8 Eur J Nucl Meden
dc.identifier.issn0340-6997-
dc.identifier.pmid10079313-
dc.identifier.doi10.1007/s002590050382-
dc.identifier.urihttp://hdl.handle.net/10541/88040-
dc.description.abstractThere are major potential advantages in non-invasive measurement of preclinical tumour biology and therapeutic response in clinically relevant, internal body sites, notably the ability to follow outcome in individual animals rather than averaging results from groups. We have exploited positron emission tomography (PET) to determine the feasibility of detecting liver metastases in B6D2F1 mice using fluorine-18 fluorodeoxyglucose ([18F]FDG) both before and after treatment by the novel cytotoxic agent, combretastatin A-4. The normal distribution of [18F]FDG in the absence of disease was characterised, with the clear delineation of the brain, the heart and the urinary bladder in all studies. In untreated mice with liver metastases, a strong correlation (r2 = 0.98) was found between the quantitative estimates of [18F]FDG uptake obtained by analysis of PET images, and those obtained from ex vivo assay of liver plus metastases excised immediately after imaging. In this first series, the effective limit of resolution was in livers containing a number of small metastases (range 8-14) with a single volume equivalent of approximately 200 mm3. PET image analysis was concordant with histological measurements in showing that single intraperitoneal doses of combretastatin A-4 resulted in an average 30% volume destruction of metastatic mass by 24 h following administration.en
dc.language.isoenen
dc.subjectLiver Canceren
dc.subjectMammary Canceren
dc.subjectCancer Transplantationen
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshFemale-
dc.subject.meshFluorine Radioisotopes-
dc.subject.meshFluorodeoxyglucose F18-
dc.subject.meshLiver Neoplasms-
dc.subject.meshMale-
dc.subject.meshMammary Neoplasms, Experimental-
dc.subject.meshMice-
dc.subject.meshNeoplasm Transplantation-
dc.subject.meshRadiopharmaceuticals-
dc.subject.meshStilbenes-
dc.subject.meshTomography, Emission-Computed-
dc.titlePositron emission tomography of murine liver metastases and the effects of treatment by combretastatin A-4.en
dc.typeArticleen
dc.contributor.departmentNorth West Medical Physics, Christie Hospital (NHS) Trust, Manchester, UK.en
dc.identifier.journalEuropean Journal of Nuclear Medicineen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.